Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
about
The therapy of insulin resistance in other diseases besides type 2 diabetesReview of nonalcoholic fatty liver disease in women with polycystic ovary syndromeNon-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Treatment of nonalcoholic steatohepatitis in adults: present and futureMechanisms of Liver Injury in Non-Alcoholic SteatohepatitisNonalcoholic fatty liver disease and aging: epidemiology to management.Bariatric surgery and non-alcoholic Fatty liver disease: current and potential future treatments.Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease, diet and gut microbiota.Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood-Adulthood Transition.Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients.Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunctionCirculating miRNA in patients with non-alcoholic fatty liver disease and coronary artery diseaseEffects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis.Metformin in the treatment of non-alcoholic fatty liver disease: safety, efficacy and mechanism.Management of fatty liver disease with the metabolic syndrome.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Routine Liver Biopsy During Bariatric Surgery: an Analysis of Evidence Base.Novel Approaches to Targeting Visceral and Hepatic Adiposities in HIV-Associated Lipodystrophy.The pharmacological management of NAFLD in children and adolescents.Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial.Cirrhosis Patients with Nonalcoholic Steatohepatitis Are Significantly Less Likely to Receive Surveillance for Hepatocellular Carcinoma.Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.Antibody-Directed Glucocorticoid Targeting to CD163 in M2-type Macrophages Attenuates Fructose-Induced Liver Inflammatory Changes.Adipocytokine expression associated with miRNA regulation and diagnosis of NASH in obese patients with NAFLD.Non-alcoholic Fatty Liver Disease: A Clinical Update.A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD.Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome.Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease.Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment.EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
P2860
Q26822399-7EE277E0-D58F-47C5-ACC7-29DBC1D91AA6Q26828765-3FF697DC-598D-4AAA-9459-7A88D83CE892Q26829503-19ECB1E3-7056-426B-8802-FDD95711C218Q26852403-C6F18844-CC29-4C96-86F8-BE1F24FF99D5Q33898945-6E8CD258-2FDD-4EC9-B541-0848B83B8FEFQ34366861-894B58D0-62E6-4810-A9C8-5A6370FC4469Q34406806-8E7C9F4A-336A-4545-B700-AE495257A55FQ34499017-48100413-51FA-4A1C-A7FE-F112409E3A9AQ35728214-EA692956-6622-4331-BE79-C4A50CFAC5DEQ35819589-29104F76-A97F-42A1-ABE9-C356A68BF600Q35847101-60883F21-7AF2-4DFA-8E90-FE59C9DAD0C0Q36323714-6E7A6546-4BC6-4ACA-BFB8-64277099C474Q36379436-02C133C5-EA3B-4D0D-8236-F2FE2DC4DDDAQ37133722-555E90F7-0644-43FC-A5A8-6194F913D99FQ37249919-AA6E49E6-7439-4621-97C8-07998295C4D4Q38192049-3C3D3EF1-F2B8-4D33-A3E3-BAC496935C66Q38199130-980D4B64-5518-4762-8106-471FBFD4E6A0Q38261236-FDEFB454-E30F-483B-9861-19EC16D38A0AQ38597198-C577B628-6876-407F-8958-E1F00622391AQ38614025-D62F1716-4B4A-4C3A-9630-3B3DAE7D7F2CQ38643266-7683A141-73EB-4FC5-A50E-E377E3BBC441Q38845334-FA62889B-7EE9-4DC8-9A69-9BA1A96C64D9Q38861564-1CAF2E42-3EEA-4014-BD2F-D635BBAEDBD3Q40214331-CE925225-AF67-40B8-B1BE-2EAAA886AC44Q41482573-1B905034-D42E-4C74-9A31-BE4C1C8A9B46Q42284206-0A8679B4-803A-4DD8-833C-01547EB69E19Q45758242-D5085495-3220-4DF7-B05B-41130B3D308AQ47100244-C67D6962-B8C2-4B1A-AC60-BA37AF291A61Q47966842-7558BDE4-3462-42E3-A755-3ABD59949FAAQ48099354-8986A5DB-BE05-4E30-84BD-19DA831518E7Q48208576-B04F9CEA-3D26-41D1-B019-FFB5D94A958EQ55323878-DFB1D50A-8D59-438D-A155-80EC2D23984EQ55497819-12D0390B-0F8E-43B7-90CA-879EC7110849
P2860
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Systematic review with meta-an ...... t based on pathogenic targets.
@en
type
label
Systematic review with meta-an ...... t based on pathogenic targets.
@en
prefLabel
Systematic review with meta-an ...... t based on pathogenic targets.
@en
P2093
P2860
P356
P1476
Systematic review with meta-an ...... t based on pathogenic targets.
@en
P2093
P2860
P356
10.1111/APT.12543
P407
P577
2013-11-10T00:00:00Z